.jpeg)
Vamorolone R&D manufacturer
Vamorolone(vamorolone) is developed by ReveraGen biopharmaceutical company in the United States. Santhera has the exclusive license for ReveraGen vamorolone for all indications worldwide. The company holds royalties to vamorolone in North America and to Sperogenix Therapeutics in China. Vamorolone has received DMD orphan drug status in the United States and Europe, Fast Track and Rare Pediatric Disease designations from the FDA in the United States, and Promising Innovative Medicines (PIM) status from the MHRA DMD in the United Kingdom. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
